Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer

Kim, Min Ok; Hong, Eui Sil; Chai, Ji Young; Leem, Joung Muk; You, Il Young; Kim, Won Dong; Park, Woo-Yoon; Kim, Seung Taik; Lee, Ki Hyeong

doi:10.4143/crt.2003.35.4.330

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite treatment with aggressive surgical resection, the overall 5-yr survival rate is only 20%, and the majority of patients relapse both locoregionally as well as at distant sites (12, 13). To overcome this poor prognosis, multimodal treatment is playing an increasingly important role in the management of esophageal cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Esophageal cancer is one of the most difficult malignancies to manage, with early extension into adventitia or through the esophageal wall, and regional lymph node involvement by the time of diagnosis. Despite treatment with aggressive surgical resection, the overall 5-yr survival rate is only 20%, and the majority of patients relapse both locoregionally as well as at distant sites ( 12 , 13 ). To overcome this poor prognosis, multimodal treatment is playing an increasingly important role in the management of esophageal cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer

et al. 2005

View full text Add to dashboard Cite

Although various combinations of chemotherapy regimens have been tried for patients with esophageal cancer, their duration of survival is extremely poor. In this study, we investigated the safety and clinical efficacy of paclitaxel and cisplatin chemotherapy in metastatic or recurrent esophageal cancer. 32 patients enrolled in this study and the median age was 60 yr. Of all the 32, 28 patients (88%) had been treated previously, 22 of them with chemotherapy or radiation therapy. All patients in the study received biweekly paclitaxel (90 mg/m2) followed by cisplatin (50 mg/m2). One patient (3%) responded completely, and 12 patients (38%) showed a partial response; in 9 patients (28%) the disease remained stable, and in 10 patients (31%) it progressed. The objective response rate was 41%. The median duration of response was 4.8 months, and the median overall survival in all patients was 7 months. The 1-yr and 2-yr survival rates were 28.1% and 7.1%, respectively. Grade 3 or 4 of neutropenia and anemia were observed in 6 (19%) and 5 (16%) patients, respectively. The major non-hematologic toxicity was fatigue, but most of them could manageable. In conclusion, biweekly paclitaxel and cisplatin is effective in patients with metastatic or recurrent esophageal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The SEA, which has been shown to be an important step for predicting possible drug target(s), was used to evaluate possible biological targets of 83b1 in cells [ 26 ]. The possible predicted protein targets with promising ligand-protein binding are shown in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

“…Here, we demonstrated that a novel quinoline derivative, 83b1, has strong inhibitory effects on tumor growth with less toxicity in non-tumor cell lines and nude mice xenograft models. The predicted target PPARδ of 83b1 has been widely reported as a cancer-promoting protein ubiquitously overexpressed in different types of cancer tissues [ 26 ]. We found that 83b1 can target PPARδ, resulting in downregulation of COX-2 mRNA expression and reduced production of PGE 2 .…”

Section: Discussionmentioning

confidence: 99%

“…3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was performed to evaluate the growth inhibitory effects of 83b1 on the six described ESCC cell lines and three immortalized non-tumor cell lines using the CellTiter96 AQueous One Solution (Promega, Madison, WI) for cell proliferation assay as previously reported [ 25 ]. In addition, a widely used anticancer drug, cisplatin (CDDP), was used as a positive control [ 26 ]. Briefly, 5×10 3 cells were seeded onto each well of the 96-well plate and allowed to grow for 24 hours.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE<sub>2</sub>

Pun

Chan

et al. 2017

Cancer Res Treat

View full text Add to dashboard Cite

Purpose83b1 is a novel quinoline derivative that has been shown to inhibit cancer growth in human esophageal squamous cell carcinoma (ESCC). This study was conducted to comprehensively evaluate the cytotoxic effects of 83b1 on a series of ESCC cell lines and investigate the mechanisms by which 83b1 suppresses cancer growth based on molecular docking analysis.Materials and MethodsA series of ESCC and nontumor immortalized cell lines were exposed to 83b1 and cisplatin (CDDP) in a dose-dependent manner, and the cytotoxicity was examined by a MTS assay kit. Prediction of the molecular targets of 83b1 was conducted by molecular docking analysis. Expression of cyclooxygenase 2 (COX-2) mRNA and COX-2–derived prostaglandin E2 (PGE2) were measured by quantitative real-time polymerase chain reaction and enzymelinked immuno-sorbent assay, respectively. In vivo anti-tumor effect was determined using a nude mice xenografted model transplanted with an ESCC cell line, KYSE-450.Results83b1 showed the significant anti-cancer effects on all ESCC cell lines compared to CDDP; however, 83b1 revealed much lower toxic effects on non-tumor cell lines than CDDP. The predicted molecular target of 83b1 is peroxisome proliferator-activated receptor delta (PPARδ), which is a widely known oncoprotein. Additionally the expression of COX-2 mRNA and COX-2–derived PGE2 were down-regulated by 83b1 in a dose-dependent manner in ESCC cell lines. Furthermore, 83b1 was shown to significantly reduce the tumor size in nude mice xenograft.ConclusionThe results of this study suggest that the potential anti-cancer effects of 83b1 on human esophageal cancers occur through the possible oncotarget, PPARδ, and down-regulation of the cancer related genes and molecules.

show abstract

Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer

Lee¹,

Kim²,

Park³

et al. 2007

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer

Abstract: S: Concurrent FP chemoradiotherapy was effective as a definitive therapy for patients with esophageal cancer. The major toxicity was mucositis. Although the treatment was relatively feasible, a randomized trial of reduced courses of chemotherapy is warranted.

Cited by 3 publications

References 0 publications

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer

Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE<sub>2</sub>

Capecitabine and Cisplatin Chemotherapy (XP) Alone or Sequentially Combined Chemoradiotherapy Containing XP Regimen in Patients with Three Different Settings of Stage IV Esophageal Cancer

Contact Info

Product

Resources

About